New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

Hidradenitis suppurativa (HS), is a chronic, recurrent dermatosis affecting skin that contains apocrine glands.

Who Took Part

According to the abstract, 11 patients were involved.

The age groups tagged for this paper are teenagers, young adults and adults, both men and women.

The researchers enrolled 11 patients with HS in the study, which was a randomized split-body study.

One side of each patient's body was treated with niosomal MB (NMB) gel and the other side was treated with unloaded (free) MB (FMB) gel.

How the Study Was Run

The design is described as randomized and single-blind.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Only one side, usually the patients, was kept unaware of whether Methylene blue (non-peptide stack partner) was given.

The affected sites were irradiated using IPL with a 630 nm filter.

Patients were followed up at 1, 3 and 6 months after treatment.

What Was Measured

Topics PubMed links to this paper include Gels, Hidradenitis Suppurativa, Liposomes, Methylene Blue, Photochemotherapy and Photosensitizing Agents.

What This Means in Plain Language

The paper is a randomized and single-blind study of Methylene blue (non-peptide stack partner) in 11 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Clinical and experimental dermatology), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.